MediWound Announces Positive Results in Its U.S. Phase I/II Study of MW005 for the…
MW005 shown to be safe and well-tolerated Data provide clinical efficacy proof-of-concept based on clearance of target lesions YAVNE, Israel, July 10, 2023 (GLOBE NEWSWIRE) --…